BGPT: Paper Review: Replication-competent fluorescent-expressing influenza B virus

Explore by Goal

Quick Explanation Copied

Paper in one line

They engineer a replication-competent influenza B virus (B/Brisbane/60/2008) that expresses mCherry or GFP fused to NS1, enabling direct fluorescence readouts for infection tracking, neutralization, and antiviral inhibition assays.

Evidence: growth kinetics/plaque phenotype appear similar to WT; fluorescence-based microneutralization and antiviral dose–response match conventional approaches in the presented comparisons.

Long Explanation

Replication-competent fluorescent-expressing influenza B virus

Virus-Reporter Engineering + Fluorescence-Based Neutralization/Antiviral Assays

DOI: 10.1016/j.virusres.2015.11.014 | Publication date (paper metadata): 2015-11-15

Core claim the paper makes

A recombinant influenza B virus (B/Brisbane/60/2008) with fluorescent protein expression enables direct identification of infected cells and supports fluorescence-based microneutralization and antiviral dose–response workflows, without relying on secondary infection readouts.

1) What they engineered (construct logic)

Fluorescent proteins (mCherry or maxGFP/Amaxa-codon-optimized GFP) are fused to the C-terminal end of viral NS1 in influenza B segment 8 (NS1/NEP ambisense region).
A PTV-1 2A autoproteolytic element and NEP coding arrangement are used so that NS1 and NEP can be translated as separate proteins, supported by prior reverse-genetics strategies.
They intentionally avoid unintended alternative splicing outcomes by introducing silent mutations in the splice acceptor site.

Figure-to-logic mapping (paper figure references)

Fig. 1A/B: schematic of the WT vs modified NS segment and where mCherry/GFP and 2A are placed.
Figs. 2–3: RNA/protein expression and functional growth/plaque phenotype.

2) Evidence that fluorescence tracks infection (and doesn’t grossly break fitness)

2.1 Molecular and cellular validation (RNA, proteins, microscopy)

They confirm the engineered genome segment by RT-PCR band sizes for WT NS vRNA vs the larger NS-mCherry vRNA, and show an mCherry-specific PCR product in infected cells; they also assay NP vRNA and cellular GAPDH mRNA as controls for infection and host transcription. . They then use Western blots to show NS1 and NS1-mCherry species and quantify that NP levels are similar between WT and mCherry viruses. Finally, in microscopy, only the infected cells with fluorescent viruses show direct mCherry fluorescence and mCherry co-distributes with viral NP and NS1 staining.

2.2 Growth kinetics and plaque phenotypes

Multicycle growth kinetics in MDCK cells at MOI=0.001 are reported as similar between WT and IBV-mCherry, with maximum titers around 72 hpi for both. . Plaque assays show infected foci/plaque sizes are similar, and all NP-positive plaques are fluorescent for mCherry viruses.

3) Quantitative readouts: neutralization (NAbs) and antivirals

3.1 Neutralizing antibodies measured by fluorescence

They pre-incubate mCherry-expressing IBV with an IBV type-specific polyclonal antibody (NR-3165) and show decreased fluorescence (infection readout) with increasing antibody concentration; they report that IAV mCherry is neutralized by the IAV-specific antibody and not the IBV antibody, i.e., reporter readout is type-specific. They also compare this fluorescence-based neutralization to conventional VN/HI-based readouts and report concordant neutralization behavior for WT vs reporter viruses.

Fig-like visualization (from Table 1): NT50 (dilution) values

Note: The source table includes “>1:200” entries. This plot shows only finite NT50 values explicitly present in Table 1 text extracted in the prompt.

3.2 Antiviral activity measured via mCherry fluorescence

They test ribavirin and amantadine against mCherry-expressing IBV and IAV. They report that both IAV and IBV-mCherry are inhibited by ribavirin dose-dependently, while amantadine inhibits mCherry-IAV but not mCherry-IBV—consistent with the expectation that amantadine targets IAV M2 but is not effective against IBV. . They also report IC50 comparisons obtained by conventional infectious readouts (FFU titration of supernatants) that are “similar within 1–2 dilution values” between WT and reporter viruses.

Fig-like visualization (from Table 3): IC50 (µM) for ribavirin and amantadine

Upper-censoring “>100” is plotted as 100 for visibility; interpret as “at least 100 µM (no detectable antiviral effect at highest tested concentration)” per the table footnote description.

4) Skeptical critique: what’s strong vs what’s uncertain

4.1 Strengths (design + readout validation)

Multiple orthogonal validations are presented: RT-PCR, Western blot, direct fluorescence microscopy, and immunofluorescence co-localization—supporting that fluorescence is biologically linked to infection rather than an artifactual expression system.
Functional equivalence checks are performed for growth kinetics and plaque phenotype, and for antiviral/neutralization dose–responses compared between WT and reporter backgrounds.

4.2 Potential blind spots / failure modes

Reporter may not be strictly linear with infectious output: fluorescence depends on expression and protein stability; changes in mCherry maturation, degradation, or translation burden could alter fluorescence without equivalent changes in infectious titers. The paper partially addresses this by comparing to FFU/VN readouts, but the equivalence is demonstrated mainly for a small set of assay conditions and compounds.
Cell-line context: the work is carried out in 293T/MDCK-based rescue and characterization. This may not capture kinetics, interferon context, or tissue-specific replication of IBV in primary respiratory epithelial contexts. The paper’s conclusions for utility are framed primarily around in vitro assay workflows.
Strain/backbone dependence: they use B/Brisbane/60/2008 (Victoria lineage). Whether the same NS1-fusion architecture preserves fitness and reporter fidelity across other IBV lineages/strains is not directly demonstrated in the provided text.
Upper-censoring complicates interpretation: for amantadine vs IBV, IC50 is “>100 µM” which indicates no detectable effect at the highest concentration tested, but it does not quantify potency beyond that cutoff.
GFP variant indicates stability differences: the paper reports GFP-expressing IBV has slightly delayed kinetics and “less stability” than mCherry, requiring serial plaque purification to obtain stable stock. This suggests reporter choice matters and could influence reproducibility across passages.

5) Reproducibility checklist (what you’d need to replicate)

Construct details: NS1 C-terminal fusion boundaries, silent splice mutations, and 2A/NEP arrangement. The paper states these were synthesized and confirmed by sequencing, but some cloning oligos are “available upon request,” which can limit fully independent recreation without access.
Assay parameters: MOIs (0.001 for multicycle), timepoints (18 hpi for imaging/molecular validation; 72 hpi for growth maxima; 48 hpi for neutralization/antiviral plate readouts), cell density, and titration methods (immunofocus FFU).
Quantification pipeline: fluorescence plate reader model (DTX-880) and dose-response fitting in GraphPad Prism.

Most falsifiable prediction implied by the paper

If fluorescence signal is a valid surrogate for infection, then (i) reporter-vs-WT virus should maintain similar growth kinetics/plaque sizes under additional conditions, and (ii) fluorescence-based IC50/NT50 should continue to match conventional infectivity-based metrics across additional drugs/antibodies and additional IBV strains.

Author reviews (open BGPT pages)

Feedback:

Updated: April 09, 2026